List of SBIR/STTR awards granted to Inhibikase Therapeutics
Inhibikase TherapeuticsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Inhibikase Therapeutics in September, 2021 for $385,888.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43NS120403-01A1 | Phase I | 385,888 | September 23, 2021 | |||||||
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in September, 2019 for $1,554,108.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44NS103695-03 | Phase II | 1,554,108 | September 30, 2019 | |||||||
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in September, 2018 for $2,002,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44CA224731-02 | Phase II | 2,002,000 | September 17, 2018 | |||||||
A SBIR Phase I contract was awarded to Inhibikase Therapeutics in September, 2017 for $284,778.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA224731-01 | Phase I | 284,778 | September 6, 2017 | |||||||
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in March, 2017 for $2,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI103982-04 | Phase II | 2,000,000 | March 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in June, 2016 for $1,787,776.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI103982-04 | Phase II | 1,787,776 | June 1, 2016 | |||||||
A SBIR Phase II contract was awarded to Inhibikase Therapeutics in September, 2017 for $3,108,583.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R44NS103695-01 | Phase II | 3,108,583 | September 1, 2017 | |||||||
A SBIR Phase I contract was awarded to Inhibikase Therapeutics for $300,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI103982-01A1 | Phase I | 300,000 | ||||||||
A SBIR Phase I contract was awarded to Inhibikase Therapeutics for $265,846.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS069213-01 | Phase I | 265,846 |
